Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives $16.71 Consensus Target Price from Analysts

by · The Markets Daily

Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) have received a consensus rating of “Moderate Buy” from the seven brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $16.71.

Several analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Ocular Therapeutix in a report on Tuesday, December 3rd. Scotiabank initiated coverage on shares of Ocular Therapeutix in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $22.00 price objective on the stock.

Read Our Latest Research Report on Ocular Therapeutix

Ocular Therapeutix Stock Performance

Shares of OCUL opened at $8.54 on Friday. Ocular Therapeutix has a 1 year low of $3.76 and a 1 year high of $11.77. The stock has a market capitalization of $1.34 billion, a PE ratio of -6.47 and a beta of 1.20. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01. The stock has a 50-day simple moving average of $9.84 and a 200-day simple moving average of $8.67.

Insider Transactions at Ocular Therapeutix

In other news, insider Jeffrey S. Heier sold 2,948 shares of Ocular Therapeutix stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $9.01, for a total transaction of $26,561.48. Following the sale, the insider now owns 269,059 shares in the company, valued at approximately $2,424,221.59. The trade was a 1.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 3.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in OCUL. Atlas Capital Advisors LLC acquired a new stake in Ocular Therapeutix during the 2nd quarter worth $34,000. Amalgamated Bank raised its holdings in shares of Ocular Therapeutix by 37.9% in the second quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 1,481 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Ocular Therapeutix by 22.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 1,015 shares during the period. Algert Global LLC purchased a new position in shares of Ocular Therapeutix during the second quarter worth about $69,000. Finally, Capital Performance Advisors LLP acquired a new position in Ocular Therapeutix in the 3rd quarter valued at about $70,000. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Ocular Therapeutix Company Profile

(Get Free Report

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

Featured Stories